These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 29413890)

  • 1. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
    Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.
    Prendergast GC; Mondal A; Dey S; Laury-Kleintop LD; Muller AJ
    Trends Cancer; 2018 Jan; 4(1):38-58. PubMed ID: 29413421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the IDO1 pathway in cancer: from bench to bedside.
    Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
    J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ups, downs and new trends of IDO1 inhibitors.
    Chen S; Tan J; Zhang A
    Bioorg Chem; 2021 May; 110():104815. PubMed ID: 33773223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
    Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heme-containing enzymes and inhibitors for tryptophan metabolism.
    Yan D; Lin YW; Tan X
    Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.
    Engin AB; Engin A
    Adv Exp Med Biol; 2024; 1460():629-655. PubMed ID: 39287867
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
    Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
    Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patent review of IDO1 inhibitors for cancer.
    Cheong JE; Ekkati A; Sun L
    Expert Opin Ther Pat; 2018 Apr; 28(4):317-330. PubMed ID: 29473428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
    Weng T; Qiu X; Wang J; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
    Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
    Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
    Amobi A; Qian F; Lugade AA; Odunsi K
    Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.